Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G13
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
STK11 deletion + KRAS mutation (6)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
CPS1 overexpression + KRAS mutation + STK11 mutation (3)
HER-2 amplification + KRAS G12D (3)
KEAP1 deletion + KRAS mutation (3)
PD-L1 overexpression + KRAS mutation (3)
EGFR exon 19 deletion + KRAS mutation (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-L/dMMR + KRAS G12V (2)
AXL overexpression + KRAS G12C (1)
CDH2 overexpression + KRAS wild-type (1)
Chr t(11;14) + KRAS mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR expression + KRAS G12C (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
FGFR1 overexpression + KRAS G12C (1)
GNA13 deletion + KRAS mutation (1)
GOPC-ROS1 fusion + KRAS Q61H (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 overexpression + KRAS wild-type (1)
IGF1R overexpression + KRAS mutation (1)
IR overexpression + KRAS mutation (1)
IRS2 amplification + KRAS mutation (1)
KEAP1 mutation + KRAS wild-type (1)
KRAS A146 + TMB-H (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS G12D + Chr del(9)(p21) (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS G12D + TP53 deletion (1)
KRAS amplification + BRAF wild-type (1)
KRAS amplification + RAS wild-type (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + BCL2A1 overexpression (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + EGFR amplification (1)
KRAS mutation + ER expression (1)
KRAS mutation + HER-2 positive (1)
KRAS mutation + HR positive (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + PIK3CA wild-type (1)
KRAS mutation + PTPN11 overexpression (1)
KRAS mutation + TP53 mutation + GNA13 deletion (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
KRAS mutation + YKL-40 overexpression (1)
KRAS wild-type + BRAF V600E (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
KRAS mutation + STK11 mutation + AXL expression (1)
MLL-AFF1 fusion + KRAS mutation (1)
MSI-H/dMMR + KRAS G12D (1)
MSI-H/dMMR + KRAS Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
MTAP deletion + KRAS G12C (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
POMK-NRG1 fusion + KRAS mutation (1)
POMK‐NRG1 fusion + KRAS G12D (1)
PTEN deletion + KRAS G12C (1)
RET positive + KRAS G12V (1)
ROS1 fusion + KRAS G12C (1)
STK11 mutation + KRAS mutation + TP53 deletion (1)
STRN-ALK fusion + KRAS G13D (1)
TP53 S12F + KRAS G12D + TMB-L (1)
HER-2 amplification + KRAS G12C (0)
PRMT5 overexpression + KRAS mutation (0)
STK11 deletion + KRAS mutation (6)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
CPS1 overexpression + KRAS mutation + STK11 mutation (3)
HER-2 amplification + KRAS G12D (3)
KEAP1 deletion + KRAS mutation (3)
PD-L1 overexpression + KRAS mutation (3)
EGFR exon 19 deletion + KRAS mutation (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-L/dMMR + KRAS G12V (2)
AXL overexpression + KRAS G12C (1)
CDH2 overexpression + KRAS wild-type (1)
Chr t(11;14) + KRAS mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR expression + KRAS G12C (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
FGFR1 overexpression + KRAS G12C (1)
GNA13 deletion + KRAS mutation (1)
GOPC-ROS1 fusion + KRAS Q61H (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 overexpression + KRAS wild-type (1)
IGF1R overexpression + KRAS mutation (1)
IR overexpression + KRAS mutation (1)
IRS2 amplification + KRAS mutation (1)
KEAP1 mutation + KRAS wild-type (1)
KRAS A146 + TMB-H (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS G12D + Chr del(9)(p21) (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS G12D + TP53 deletion (1)
KRAS amplification + BRAF wild-type (1)
KRAS amplification + RAS wild-type (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + BCL2A1 overexpression (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + EGFR amplification (1)
KRAS mutation + ER expression (1)
KRAS mutation + HER-2 positive (1)
KRAS mutation + HR positive (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + PIK3CA wild-type (1)
KRAS mutation + PTPN11 overexpression (1)
KRAS mutation + TP53 mutation + GNA13 deletion (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
KRAS mutation + YKL-40 overexpression (1)
KRAS wild-type + BRAF V600E (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
KRAS mutation + STK11 mutation + AXL expression (1)
MLL-AFF1 fusion + KRAS mutation (1)
MSI-H/dMMR + KRAS G12D (1)
MSI-H/dMMR + KRAS Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
MTAP deletion + KRAS G12C (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
POMK-NRG1 fusion + KRAS mutation (1)
POMK‐NRG1 fusion + KRAS G12D (1)
PTEN deletion + KRAS G12C (1)
RET positive + KRAS G12V (1)
ROS1 fusion + KRAS G12C (1)
STK11 mutation + KRAS mutation + TP53 deletion (1)
STRN-ALK fusion + KRAS G13D (1)
TP53 S12F + KRAS G12D + TMB-L (1)
HER-2 amplification + KRAS G12C (0)
PRMT5 overexpression + KRAS mutation (0)
›
Associations
(8)
News
Trials
Search handles
@BijoyTelivala
@GarridoLagunaMD
@HHorinouchi
@SyedAAhmad5
@pashtoonkasi
@weldeiry
Search handles
@BijoyTelivala
@GarridoLagunaMD
@HHorinouchi
@SyedAAhmad5
@pashtoonkasi
@weldeiry
Filter by
Latest
11ms
BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12A • KRAS G12 • KRAS G13 • KRAS Q61H • KRAS A146V • KRAS G13C
|
BI-2493
1year
Very interesting! KRAS codon G12 mutations as a resistance biomarker on TAS102 for metastatic CRC? Pts with KRAS G13 codon mutations did better? @pashtoonkasi @GIcancerDoc @the_danielahn @IbrahimSahinMD1 @jonathanloree Comments? #CRCSM https://t.co/kRGjtmEmmp (@manjuggm)
1 year ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12 • KRAS G13
|
Lonsurf (trifluridine/tipiracil)
1year
Has anyone looked at kras G13 in pancreas cancer? @Aiims1742 @DrJashDatta @NbmerchantMD @AndrewMWaters @krushnacpatra https://t.co/vW4suPAZ5U (@SyedAAhmad5)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G13
over1year
Data presented by @tajiknia #AACRJCA22 shows MRTX1133 suppression of pERK at nM doses & synergies with 5-FU in CRC & pancreatic cancer cells with #KRAS G12D, G12V, & G13D. More studies needed before excluding non-G12D mutations from trials @BrownUCancer @BrownMedicine #eldeirylab https://t.co/DUlynIqYZH (@weldeiry)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12 • KRAS G13
|
5-fluorouracil • MRTX1133
over3years
Question that came up in our KRAS clinical trial group in @colontown. Does KRAS G13D mCRC respond differently to anti-EGFR abs? What papers show this? TY @pashtoonkasi @agrothey @doctorC369 (@manjuggm)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G13D • KRAS G13
over3years
I guess not all of us agree with this abstract conclusions. How can cfDNA guide treatment decisions in adjuvant setting in 2020? It simply can not unless one believes exploratory analysis, not even done with same test. Remind me story with Kras G13D an anti-EGFR in mCRC... (@GarridoLagunaMD)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G13D • KRAS G13
over3years
86 year old metastatic lung cancer with a malignant pleural effusion . Ecog Ps 0 PD L1 is 80 % Foundation 1 shows exon 14 met+ NF1+Nfkbia+ Tet2+Kras G13D+ RET What would be the first line treatment ? Pembro alone vs Capmatinib? @HosseinBorghaei @JackWestMD @PatelOncology (@BijoyTelivala)
over 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TET2 (Tet Methylcytosine Dioxygenase 2) • NFKBIA (NFKB Inhibitor Alpha 2)
|
KRAS G13D • KRAS G13
|
Keytruda (pembrolizumab) • Tabrecta (capmatinib)
almost4years
Since the 💧#ptDNA [Peritoneal Tumor DNA] can be tested using simple & cost effective methods (Droplet digital PCR (ddPCR) using a commercially available screening kits, in 👆🏾it was a KRAS G12/G13 kit), it could be paired with some of the available🩸#ctDNA to ⬆️sensitivity.💡 (@pashtoonkasi)
almost 4 years ago
HEOR
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12 • KRAS G13
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login